Enanta Pharmaceuticals (NASDAQ:ENTA) Issues Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its earnings results on Monday. The biotechnology company reported ($1.07) earnings per share for the quarter, topping the consensus estimate of ($1.43) by $0.36, Briefing.com reports. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. The firm had revenue of $17.97 million for the quarter, compared to analyst estimates of $17.44 million. During the same period last year, the company earned ($1.27) earnings per share. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis.

Enanta Pharmaceuticals Trading Up 1.2 %

Shares of Enanta Pharmaceuticals stock opened at $13.00 on Wednesday. The stock has a 50-day moving average price of $13.57 and a 200 day moving average price of $13.76. The company has a market cap of $275.33 million, a P/E ratio of -2.08 and a beta of 0.60. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $19.98.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ENTA. JPMorgan Chase & Co. decreased their price target on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday. JMP Securities decreased their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 7th. Finally, StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.83.

Insider Buying and Selling

In other news, insider Scott T. Rottinghaus sold 4,299 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the transaction, the insider now owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tara Lynn Kieffer sold 7,266 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.33, for a total value of $89,589.78. Following the transaction, the insider now directly owns 32,341 shares in the company, valued at approximately $398,764.53. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,940 shares of company stock valued at $246,181. Corporate insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.